ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks

[1] Flather M.D.(2000)Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet 355 1575-1581

[2] Yusuf S.(1992)Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 669-677

[3] Kober L.(2003)Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease Am J Cardiol 91 30H-37H

[4] Pfeffer M.A.(2009)Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials Curr Diab Rep 9 1-3

[5] Braunwald E.(2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 772-776

[6] Moye L.A.(2001)A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 1667-1675

[7] McFarlane S.I.(2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 767-771

[8] Kumar A.(2006)Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition Int J Cardiol 106 367-372

[9] Sowers J.R.(2005)Update on the role of the AT2 receptor Curr Opin Nephrol Hypertens 14 67-71

[10] McFarlane S.I.(2008)Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 30-48

[1] Flather M.D.(2000)Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet 355 1575-1581

[2] Yusuf S.(1992)Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 669-677

[3] Kober L.(2003)Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease Am J Cardiol 91 30H-37H

[4] Pfeffer M.A.(2009)Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials Curr Diab Rep 9 1-3

[5] Braunwald E.(2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 772-776

[6] Moye L.A.(2001)A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 1667-1675

[7] McFarlane S.I.(2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 767-771

[8] Kumar A.(2006)Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition Int J Cardiol 106 367-372

[9] Sowers J.R.(2005)Update on the role of the AT2 receptor Curr Opin Nephrol Hypertens 14 67-71

[10] McFarlane S.I.(2008)Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 30-48